Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 125 of 148 entries
View as:

Bevacizumab, Oxaliplatin, and Docetaxel in Treating Patients With Locally Advanced Unresectable or Metastatic Stomach or Gastroesophageal Junction Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00217581 Org: User:
Start: 10/31/04 End: 01/31/13 Due: 01/31/14

MK-3475 as Maintenance Therapy in Extensive Stage SCLC

Phase: N/A Priority: Normal
NCT ID: NCT02359019 Org: User:
Start: 02/28/15 End: 10/31/18 Due: 10/31/19

Fludeoxyglucose F 18-PET/CT Scans in Patients Receiving Ultra Short-Term Dexamethasone For Lung Nodules

Phase: N/A Priority: Normal
NCT ID: NCT00906503 Org: User:
Start: 04/30/09 End: 04/30/12 Due: 04/30/13

ESK981 and Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04159896 Org: User:
Start: 11/13/19 End: 03/01/22 Due: 03/01/23

Trial of Loncastuximab Tesirine in High Risk Diffuse Large B-cell Lymphoma Post Transplant

Phase: N/A Priority: Normal
NCT ID: NCT05222438 Org: User:
Start: 04/08/22 End: 12/31/25 Due: 12/31/26

Identification of Biomarkers for Early Detection of Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00897494 Org: User:
Start: 02/28/05 End: 04/30/11 Due: 04/30/12

Reducing Metabolic Syndrome Among Breast Cancer Survivors

Phase: N/A Priority: Normal
NCT ID: NCT03719677 Org: User:
Start: 11/06/18 End: 09/13/20 Due: 09/13/21

Bevacizumab in Treating Patients With Relapsed Prostate Cancer That Did Not Respond to Hormone Therapy

Phase: N/A Priority: Normal
NCT ID: NCT01656304 Org: User:
Start: 05/31/07 End: 06/30/12 Due: 06/30/13

Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01812668 Org: User:
Start: 03/31/13 End: 06/18/19 Due: 06/18/20

A Nutritional Supplement Capsule Containing Curcumin, Green Tea Extract, Polygonum Cuspidatum Extract, and Soybean Extract in Healthy Participants

Phase: N/A Priority: Normal
NCT ID: NCT00768118 Org: User:
Start: 04/30/08 End: 09/30/08 Due: 09/30/09

Ph II Long Term/Low Dose Xeloda in Head and Neck Squamous Cell Carcinoma After Surgery, Radiation & or Chemo

Phase: N/A Priority: Normal
NCT ID: NCT00258310 Org: User:
Start: 12/31/03 End: 02/28/11 Due: 02/28/12

Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00248482 Org: User:
Start: 02/28/02 End: 01/31/08 Due: 01/31/09

Studying Biomarkers in Tumor Tissue and Blood Samples From Patients Undergoing Chemotherapy and Radiation Therapy for Stage II or Stage III Rectal Cancer That Can Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT00960427 Org: User:
Start: 06/30/09 End: 04/30/10 Due: 04/30/11

Carboplatin, Everolimus, and Prednisone in Treating Patients With Metastatic Prostate Cancer That Progressed After Docetaxel

Phase: N/A Priority: Normal
NCT ID: NCT01051570 Org: User:
Start: 02/28/10 End: 09/30/13 Due: 09/30/14

Isoflavones and Radiation Therapy in Treating Patients With Localized Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00243048 Org: User:
Start: 05/31/02 End: 10/31/07 Due: 10/31/08

Integration of Neutron Therapy in the Treatment Plan for Stage III Non-Small Cell Lung Cancer (NSCLC)

Phase: N/A Priority: Normal
NCT ID: NCT01416961 Org: User:
Start: 08/31/11 End: 12/31/11 Due: 12/31/12

Music in Reducing Distress in Participants with Cancer During Chemotherapy Treatment

Phase: N/A Priority: Normal
NCT ID: NCT03683420 Org: User:
Start: 02/14/18 End: 12/31/20 Due: 12/31/21

Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00248560 Org: User:
Start: 01/31/05 End: 06/30/12 Due: 06/30/13

Pyrazoloacridine in Treating Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00002656 Org: User:
Start: 10/31/95 End: 02/29/08 Due: 02/28/09

F-Tryptophan PET/CT in Human Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05556473 Org: User:
Start: 09/29/22 End: 12/31/26 Due: 12/31/27

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00066326 Org: User:
Start: 06/30/03 End: 09/30/05 Due: 09/30/06

DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00972023 Org: User:
Start: 02/28/10 End: 08/22/10 Due: 08/22/11

Diindolylmethane in Treating Patients With Stage I or Stage II Prostate Cancer Undergoing Radical Prostatectomy

Phase: N/A Priority: Normal
NCT ID: NCT00888654 Org: User:
Start: 08/31/09 End: 04/30/14 Due: 04/30/15

Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies

Phase: N/A Priority: Normal
NCT ID: NCT01643603 Org: User:
Start: 05/31/12 End: 10/09/18 Due: 10/09/19

Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT01270880 Org: User:
Start: 01/31/11 End: 07/31/14 Due: 07/31/15